Apple Hands Secret Blood Glucose Project to Zongjian Chen as Hardware Overhaul Accelerates

But the handoff is not a promise of an imminent launch. The same reporting makes clear that a consumer-ready non-invasive glucose monitor remains "years away" from appearing in an Apple Watch . The switch signals a shift from early feasibility work to a more deliberate engineering phase—moving the project, in effect, from the lab bench to the advanced product pipeline under one of Apple's most trusted hardware leaders.

The New Lead: Zongjian Chen

Zongjian Chen runs Apple's Advanced Technologies Group and already oversees core hardware programs including the company's in-house modem efforts . In a broader reorganization two weeks earlier, Chen's responsibilities had already grown when Johny Srouji, Apple's new chief hardware officer, expanded his portfolio beyond modems . Now the glucose project falls under him as well.

The previous leader, Tim Millet, had taken over the exploratory effort in September 2023 after the unexpected death of its original head, scientist Bill Athas . Millet's appointment was intended to infuse the team with the discipline of Apple's chip organization—he is credited with leading the transition to Apple Silicon . Chen's appointment, by contrast, moves the project out of platform architecture entirely and places it inside the hardware group that actually shepherds technologies into shipping devices.

The Broader Restructuring Under Johny Srouji

The leadership change is just one piece of a larger hardware reorganization at Apple. In early 2026, Johny Srouji was promoted to chief hardware officer and immediately began two rounds of restructuring. The first round distributed Srouji's former direct responsibilities downward. The second, announced on May 19, 2026, overhauled product-design management by moving longtime executive Kate Bergeron into a product-reliability role and splitting her design duties between two deputies, Shelly Goldberg and Dave Pakula .

The rationale is speed. By placing E5 under Chen, Srouji appears to be consolidating advanced technologies under proven leaders and moving promising research closer to the product pipeline. Several people inside Apple, Gurman reports, view the handoff as a sign the work is progressing to a stage where Chen can "ramp up development of the technology into an eventual consumer-grade offering" .

The 15-Year History of E5

Apple's quest for non-invasive blood sugar monitoring originated well over a decade ago during the Steve Jobs era . The initiative, called E5, was reportedly spurred by Jobs himself, who directed Apple to acquire a small startup named RareLight in 2010 that was pursuing optical glucose measurement .

The work lives inside Apple's Exploratory Design Group (XDG), a skunkworks division that has operated with extraordinary secrecy . The team has already met what Apple considers "major milestones" in proving the underlying science, reaching a proof-of-concept stage in early 2023 . According to earlier Bloomberg reports, the project has involved hundreds of engineers and has produced prototypes roughly the size of an iPhone .

The Technology: Silicon Photonics on a Chip

E5's approach relies on a class of optical sensor technology called silicon photonics. Rather than piercing the skin, the system fires lasers built into a silicon chip through the skin into the interstitial fluid beneath. By measuring how much light is absorbed at specific wavelengths, the device can estimate the concentration of glucose .

This optical path is distinct from the electrical-sensor methods used in many traditional continuous glucose monitors, which typically require a tiny filament inserted under the skin. Apple's bet is that silicon photonics can eventually deliver medical-grade accuracy in a non-invasive form factor small enough for an Apple Watch. That miniaturization is one of the remaining technical hurdles; the current prototypes are still too large for a wrist-worn device .

Why a Product Is Still Years Away

The leadership change does not change the timeline. Gurman's May 26, 2026 newsletter explicitly states that the feature will not appear in the Apple Watch this year, and it may not arrive next year either . The challenge now is not proving the physics—Apple's XDG team already did that—but shrinking the hardware to fit on a wrist, meeting reliability and accuracy standards expected of a health sensor, and scaling manufacturing at Apple's volumes.

Medical accuracy, in particular, is a high bar. A consumer glucose monitor used by people with diabetes would likely need to meet regulatory standards for clinical accuracy, which adds a layer of testing and validation beyond a typical consumer-electronics launch. Gurman and other Apple watchers have consistently described the feature as a moonshot—an ambitious, high-difficulty effort that Apple has pursued for more than 15 years without a ship date .

What the Shift Means for the Apple Watch

The Apple Watch's health-sensing roadmap has been a key differentiator, and glucose monitoring remains one of the most requested features the device still lacks. The leadership change signals that Apple is putting additional engineering weight behind the initiative at a time when the watch business faces competition from screenless wearables from companies like Whoop and Oura .

But for now, the takeaway is measured rather than triumphant. Apple is moving the right pieces: a proven delivery leader, a clearer reporting structure under Srouji, and an organizational home inside advanced hardware rather than early-stage research. The E5 project is making progress, but progress at Apple scale is slow—and the "years away" caveat that accompanies every report on the effort remains firmly in place.